european manufacturer, page-17

Thanks for reminding me about the May'10 ann. Apologies; my earlier post should have been clearer. "Packaging and dispensing" referred to the way in which the vaccine will be delivered to the patient's body i.e. the therapeutic regime that provides the best outcome for the patient. I would guess that the details of this regime are not currently known (although Phase II trial results would indicate the most likely place to start looking) and Phase III results, if successful, will go a long way towards defining the regime. The Fraunhofer Institute has the expertise to develop the vaccines and set up the trials but, and correct me if I am wrong, PRR holds the IP rights to the vaccine and ultimately the product.

PRR and DNDN's products are based on immunotherapy and the FI is one of the world's foremost immunotherapy R&D organisations; by leveraging off the FI's expertise both PRR and DNDN will benefit. Additionally, because PRR and DNDN's products target different cancers there should be no conflict of interest. The FI should benefit greatly from the collaboration with both companies probably through licensing agreements i.e. something along the lines of licensing the rights to the know-how behind the therapeutic regime and delivery mechanism to PRR and again to DNDN at a later stage for a different regime.

The synergies between these organisations suggest that further breakthroughs in cancer therapy are just around the corner.